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1. Introduction
Angiogenesis is the formation of new blood vessels from the existing vasculature, and neo‐
vascularization is a prerequisite for the growth of solid tumors beyond 1-2 mm in diameter
[1]. Because of this, during tumorigenesis, tumor growth reaches a growth-limiting step
where oxygen and nutrient levels are insufficient to continue proliferation.
Tumors acquire blood vessels by co-option of neighboring vessels from sprouting or intus‐
suscepted microvascular growth and by vasculogenesis from endothelial precursor cells [2].
In most solid tumors the newly formed vessels are plagued by structural and functional ab‐
normalities due to the sustained and excessive exposure to angiogenic factors produced by
the tumor [3]. As a result of this, the new tumor-associated vasculature is abnormal and in‐
efficient, but it is essential for tumor growth and metastasis. Despite being abnormal, these
new vessels allow tumor growth at early stages of carcinogenesis and progression from in
situ lesions to locally invasive, and eventually to metastatic tumors.
As a result, tumors tend to become hypoxic. The normal cellular response to hypoxia is to
produce growth factors such as vascular endothelial growth factor (VEGF), transforming
growth factor alpha (TGF-α), and platelet derived growth factor (PDGF), by neoplastic, stro‐
mal cells or inflammatory cells [4], and may trigger an angiogenic switch to allow the tumor
to induce the formation of microvessels from the surrounding host vasculature [5], that
stimulate neoangiogenesis [6].
VEGF is the most potent and specific growth factor for endothelial cells, and is associat‐
ed with tumor vessel density, cancer metastasis,  and prognosis [7-10]:  high levels of cir‐
culating VEGF have been reported in patients with non-small  cell  lung cancer (NSCLC)
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[7,10-18].  VEGF is  continuously  expressed  throughout  the  development  of  many tumor
types,  and is  the  only  angiogenic  factor  known to  be  present  throughout  the  entire  tu‐
mor life cycle [19]. The clinical significance of circulating levels of VEGF in patients with
NSCLC is controversial.
Since tumor growth and metastasis are angiogenesis-dependent, relying upon the genera‐
tion of new blood vessels to sustain proliferation, survival and spread of the malignant cells,
therapeutic strategies aimed at inhibiting angiogenesis area theoretically attractive. Target‐
ing and damaging blood vessels can potentially kill thousands of tumor cells. The antiangio‐
genesis and vascular targeting strategies, therefore, may no result in whole tumor cell kill,
but may maintain stable disease: this has given rise to the concept cytostatic paradigm [20].
The investigation and development of different anti-angiogenesis and vascular targeting
strategies are of interest with respect to lung cancer.
2. Hypoxia and lung cancer, HIF-1α, carbonic anhydrase IX and glucose
transporter glut
Hypoxia is one of the most important challenges for tumor growth and survival. The angio‐
genesis is a fundamental to avoid tumor necrosis (TN); every cell in a tissue is forced to be
within 100μm capillary blood vessel [5].
Hypoxia inducible factor-1 (HIF-1) is a regulator of VEGF under hypoxia conditions [21].
HIF-1 is a heterodimer consisting of 2 subunits, HIF-1α and HIF-1β (otherwise known as the
aryl hydrocarbon receptor nuclear translocator), which is stabilized by hypoxia. The expres‐
sion of these subunits is different; HIF-1β is constitutively expressed, unlike HIF-1α, which
is rapidly degraded under normoxic conditions [22]. In the presence of oxygen, HIF-1α is
hydroxylated on conserved prolyl residues within the oxygen-dependent degradation do‐
main by prolylhydroxylases and binds to von Hippel-Lindau protein (pVHL), which in turn
targets it for degradation through the ubiquitin-proteasome pathway [23-26]. Hypoxia in‐
hibits hydroxylation of prolyl residues 402 and 564 in the oxygen-dependent degradation
domain that avoid binding of the pVHL. Similar hypoxia-dependent inhibition of hydroxy‐
lation of asparagines residues within the C-terminal activation domain increases HIF-1α
transcriptional activity. Oxygen-dependent degradation of HIF-1α is inhibited by src and ras
oncogenes [22-25].
The HIF-1 complex recognizes hypoxia response elements on the promoter of several genes,
including VEGF, PDGF, and TGF-α [26].
Growth factors, cytokines and oncogenes, which stimulate p42/p44 mitogen-associated pro‐
tein kinase (MAPK) and/or phosphoinositidyl-3 kinase (PI-3K) pathways, may enhance
HIF-1 activity. HIF-1 binds to a conserved sequence (5-CGTG-3) known as the hypoxic re‐
sponse element in the promoter region of its target genes. These target genes are involved in
processes that promote cellular survival, angiogenesis, blood vessel vasodilatation, erythro‐
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poiesis, anaerobic metabolism, buffering of the intracellular compartment and induction of
growth factors. HIF-1 activity in vivo promotes tumor growth in the most of the studies and
resistance to several chemotherapy agents, as platinum compounds [22]. Carbonic anhy‐
drase (CA) IX and glucose transporter-1 are other transcriptional targets of HIF-1 and, along
with HIF-1, have been identified as novel markers of hypoxia in different tumor types
[27-31]. Up-regulation of CA IX in vivo in a perinecrotic pattern suggests this may be an im‐
portant pathway in hypoxia, possibly regulating pH to allow survival of cells under hypoxic
conditions [28].
Other study showed that HIF-1 is commonly expressed in NSCLC and is involved in the
pathogenesis  of  NSCLC.  HIF-1  expression  seems  associated  with  a  poor  prognosis  and
this was found to be as an independent factor. A similar observation has been made for
the prognostic impact of the extent of TN, another marker for hypoxia in NSCLC, where
although extensive TN predicts outcome in earlier stages of the disease, no such effect is
seen in locally advanced disease. Thus, a number of other studies have included patients
with  locally  advanced disease  in  different  cancer  types  and reported an association be‐
tween HIF-1 expression and prognosis  [22].  Although some other studies have reported
different results [32].
The associations between HIF-1, CA IX, TN and squamous NSCLC are coherent with the
known pathways that regulate and are regulated by HIF-1. CA IX is regulated by HIF-1. TN
and CA IX have been associated with a poor prognosis in NSCLC [22,31].
By other hand, glucose transporter GLUT-1 is a potential intrinsic marker of hypoxia in can‐
cer [29]. VEGF and GLUT-1 are similarly regulated in response to hypoxia [33]. They may
functionally help each other to endure hypoxia. Therefore, an upregulated expression of
GLUT-1 allows the cell to better use an inadequate source of glucose, while an upregulated
expression of VEGF will improve the reserve of glucose and oxygen through the recruitment
of additional blood vessels [33].
3. Pathophysiology and clinical implications of VEGF
The role of angiogenesis in cancer biology was defended by Folkman in 1971, who first
postulated that solid tumors remained latent at a specific size due to the absence of neovas‐
cularization, that was conditioned by the diffusion of oxygen and nutrients [34].
Subsequent studies have shown that angiogenesis is involved in tumor development from
the initial stages to the most advanced stages of the disease [35]. Angiogenesis plays there‐
fore, an important role in tumor growth and metastasis development.
Since then, one of the most important questions has been the identification of proangio‐
genic  factors  and the mechanisms in order to  block its  action.  One of  the most  studied
has been the VEGF.
VEGF is a potent mediator of angiogenesis. It is a growth factor that stimulates the prolifera‐
tion and migration, promotes survival, inhibits apoptosis and regulates the permeability of
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vascular endothelial cells. It belongs to the growth factors family, which includes four ho‐
mologues VEGF-A (commonly referred to as VEGF)-B, -C, -D, -E and placental growth fac‐
tor (PIGF). The biological activity of VEGF is mediated by binding to receptors with tyrosine
kinase activity VEGFR-1 (also known as fms-like tyrosine kinase 1, ftl-1), VEGFR-2 (also
known as kinase-insert domain receptor, KDR) and VEGFR-3 (ftl4).
When VEGF binds to its receptors it causes receptor dimerization, autophosphorylation, and
downstream signaling of different pathways, as v-src sarcoma viral oncogene homolog
(Src), phosphoinositol (PI)-3 kinase (PI3K) and phospholipase-C γ (PLCγ) which activate
proliferation and angiogenesis.
In animal tumor models, VEGF is produced both by tumor cells and also by stromal tissues [4].
VEGF and its receptor are expressed in tumor cells in both small cell lung cancer (SCLC)
and non-small cell lung cancer (NSCLC) [36,37]. It is involved in tumor growth by neoangio‐
genesis, lymphangiogenesis and lymph nodal dissemination [38]. High levels of VEGF have
been correlated with poor prognosis [39]. But there are several questions about the role of
VEGF levels and its various isoforms plays as a potential biomarker, which may be useful in
the use and selection of therapies against it. VEGF levels are elevated in lung cancer patients
when compared to controls [40]. There is also a correlation between VEGF levels and the
clinical stage in NSCLC patients [7,10,13,15] and an inverse correlation between the VEGF
serum levels and survival [41]. Low levels of VEGF have shown to be correlated with a good
response to chemotherapy [12]. Moreover, a study showed that low levels of VEGF were
correlated with a good response to anti-EGFR. Furthermore, levels of VEGF in responders
were not significantly different from volunteers, but were different from non-responders
[42]. However, it remains unclear whether the clinical effects of anti-EGFR in patients with
NSCLC are correlated with reductions in the levels of angiogenic growth factors. Further‐
more, it is unclear whether these factors are correlated with response to anti-EGFR treat‐
ment, blocking EGFR autophosphorylation [43] and the subsequent signal transduction
pathways implicated in proliferation, metastasis and inhibition of apoptosis, as well as an‐
giogenesis [44,45]. The inhibition of EGFR has been shown to reduce production of angio‐
genic growth factors in various types of cancer cells [45,46].
Antiangiogenic drugs have demonstrated efficacy in the treatment of NSCLC in the last
years. The more tested antiangiogenic drug in lung cancer is bevacizumab, a monoclonal an‐
tibody directed against VEGF, which is the first antiangiogenic approved for treatment of
metastatic NSCLC in combination with chemotherapy. Two phase III studies have assessed
the efficacy of chemotherapy combinations associated with bevacizumab. The AVAiL study
[47] analyzed the combination of cisplatin and gemcitabine with or without bevacizumab in
first line treatment for NSCLC. The primary endpoint was reached, showing a benefit in
progression-free survival in the bevacizumab arm. The second study [48] compared the ad‐
dition of bevacizumab with carboplatin and paclitaxel regimen, aiming differences in over‐
all survival, progression-free survival and response rate.
These detailed studies further in subsequent chapters, show that bevacizumab is an effective
and safe drug in the treatment of advanced NSCLC.
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4. Pathophysiology and clinical implications of EGF/PDGF/VEG
It is known that other several growth factors regulate developmental processes, among
which are the Epidermal Growth Factor (EGF), Fibroblast Growth Factor (FGF), growth fac‐
tor Insulin-like type I (IGF-I) and Platelet Derived Growth Factor platelet (PDGF).
4.1. EGF
Members of the EGF family of peptide growth factors serve as agonists for ErbB family re‐
ceptors. They include EGF, TGFα, amphiregulin (AR), betacellulin (BTC), heparin-binding
EGF-like growth factor (HB-EGF), epiregulin (EPR), epigen (EPG), and the neuregulins
(NRGs).
EGF is a polypeptide of 53 amino acids (6 Kda) that appears as a product of proteolytic proc‐
essing of a large protein integral membrane (1207aa). This precursor protein is consisting of
8 domains called EGF-like, of which only one is active. The gene corresponding to this
growth factor is located on chromosome 4q25 and stimulates epithelial cell proliferation, on‐
cogenesis and is involved in wound healing. Its three-dimensional structure is characterized
by the presence of common domain to other family ligands. This protein shows a strong se‐
quential and functional homology with TGFα, which is a competitor for EGF receptor sites.
Collectively, these agonists regulate the activity of the four ErbB (Erythroblastic Leukemia
Viral Oncogene Homolog) family receptors, each of which appears to make a unique set of
contributions to a complicated signaling network.
EGF binds to a specific receptor on the surface of responsive cells known as EGFR (Epider‐
mal growth factor receptor). EGFR is a member of the ErbB family receptors, a subfamily of
four closely related to tyrosine kinase receptors: EGFR (ErbB1), Her2/c-neu (ErbB2), Her3
(ErbB3) and Her4 (ErbB4) (Fig.1). The EGF family ligands exhibits a complex pattern of in‐
teractions with the four ErbB family receptors; for example, EGFR can bind eight different
EGF family members and Neuregulin 2beta (NRG2β) binds EGFR, ErbB3 and ErbB4. Given
that ErbB2 lacks an EGF family ligand, ErbB3 lacks kinase activity, and the four ErbB recep‐
tor display distinct coupling patterns to different signaling effectors in the affinity of a given
EGF family member as a key determinant of specificity for the ligand [49].
In response to toxic environmental stimuli,  such as ultraviolet irradiation, or to receptor
occupation  by  EGF,  the  EGFR  forms  Homo-  or  Heterodimers  with  other  family  mem‐
bers. Binding of EGF to the extracellular domain of EGFR leads to receptor dimerization,
activation  of  the  intrinsic  PTK  (Protein  Tyrosine  Kinase),  tyrosine  autophosphorylation,
and recruitment of  various signaling proteins to these autophosphorylation sites located
primarily  in  the  C-terminal  tail  of  the  receptor.  Tyrosine  phosphorylation  of  the  EGFR
leads  to  the  recruitment  of  diverse  signaling  proteins,  including  the  Adaptor  proteins
GRB2 (Growth Factor  Receptor-Bound Protein-2)  and Nck (Nck Adaptor  Protein),  PLC-
&γ;  (Phospholipase-C-γ),  SHC  (Src  Homology-2  Domain  Containing  Transforming  Pro‐
tein),  STATs  (Signal  Transducer  and  Activator  of  Transcription),  and  several  other
proteins and molecules (Fig 2).
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Figure 1. The binding of specific ligands to the receptor activates EGFR and generates a signal transduction cascade
through its 2-way main PI3K/Akt and Ras / Raf / MAPK eventually stimulate proliferation, cell cycle progression, repair,
angiogenesis and invasion.
Figure 2. Binding specificities of EGF-related peptide growth factors
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Although EGFR plays  an  important  role  in  maintaining  normal  cell  function,  deregula‐
tion of EGFR pathway contributes to the development of malignancy progression, inhibi‐
tion  of  apoptosis,  induction  of  angiogenesis,  promotion  of  tumor-cell  motility  and
metastasis.  Aberrant  regulation of  the activity or  action of  EGFR and other members of
the RTK family have been involved in multiple cancers,  including of brain,  lung, breast
and ovary. Furthermore, in many tumors EGF-related growth factors are produced either
by the tumor cells themselves or are available from surrounding stromal cells, leading to
constitutive  EGFR  activation.  In  gliomas,  EGFR  amplification  is  often  accompanied  by
structural rearrangements that cause in-frame deletions in the extracellular domain of the
receptor,  the  most  frequent  is  the  EGFRvIII  variant.  Somatic  mutations  in  the  tyrosine-
kinase domain of EGFR were also identified in NSCLC.
When mutated, EGFR tyrosine kinase is constitutively activated, resulting in uncontrolled
proliferation, invasion and metastasis. Expression of EGFR and their ligands, especially
TGFα, by lung cancer cells, indicates the presence of an autocrine (self-stimulatory) growth
factor loop. Activating EGFR mutations are observed in approximately 10% of North Ameri‐
can and European populations and 30% to 50% of Asian populations [50] and are signifi‐
cantly more common in never-smokers (100 or less cigarettes per lifetime) or light former
smokers (quit 1 year or more ago and less than ten-pack per year smoking history). The leu‐
cine to arginine substitution at position 858 (L858R) in exon 21 and short in-frame deletions
in exon 19 are the most common mutations seen in adenocarcinomas of the lung. These mu‐
tations result in prolonged activation of the receptor and downstream signaling through
phosphorylated Akt, in the absence of ligand stimulation of the extracellular domain. EGFR
mutations are both prognostic for response rate to chemotherapy and survival irrespective
of therapy and are predictive of response to specific inhibitors of the EGFR tyrosine kinase.
4.2. PDGF
Platelet-derived growth factor (PDGF) is a major mitogen for fibroblasts, smooth muscle
cells (SMCs), and glia cells. Originally, was identified as a constituent of whole blood serum
that was absent in cell-free plasma-derived serum, and was subsequently purified from hu‐
man platelets [51]. Although the α-granules of platelets are a major storage site for PDGF,
can be synthesized by a number of different cell types including fibroblasts, muscle, bone /
cartilage, and connective tissue cells.
The synthesis is often increased in response to external stimuli, such as exposure to low oxy‐
gen tension, thrombin, or stimulation with various growth factors and cytokines [52].
PDGF is a family of cationic homo- and heterodimers of disulphide-bonded polypeptide
chains. In mammals, a total of four different genes encode four PDGF chains (PDGF-A,
PDGF-B, PDGF-C, and PDGF-D), which are assembled in five different isoforms known as:
AA, AB, BB, CC and DD [53]. All members carry a growth factor core domain containing a
conserved set of cysteine residues. The core domain is necessary and sufficient for receptor
binding and activation. Classification into PDGFs is based on receptor binding. It has been
generally assumed that PDGF is selective for their owns receptors.
Angiogenesis and Lung Cancer
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PDGF isoforms exert their effects on target cells by activating two structurally related pro‐
tein tyrosine kinase receptors. The α and β receptors have molecular sizes of 170 and 180
kda, respectively, after maturation of their carbohydrates. Extracellularly, each receptor con‐
tains five immunoglobulin-like domains, and intracellularly there is a tyrosine kinase do‐
main that contains a characteristic inserted sequence without homology to kinases.
The human α-receptor gene is localized on chromosome 4q12, close to the genes for the SCF
(stem cell factor) receptor and VEGF receptor-2, and the β-receptor gene is on chromosome 5
close to the CSF-1 (colony stimulating factor-1) receptor gene [54].
Because PDGF isoforms are dimeric molecules, they bind two receptors simultaneously and
dimerize receptors upon binding. The α receptor binds both the A and B chains of PDGF
with high affinity, whereas the β receptor binds only the B chain with high affinity. There‐
fore, PDGF-AA induces αα receptor homodimers, PDGF-AB αα receptor homodimers or αβ
receptor heterodimers, and PDGF-BB all three dimeric combinations of α and β receptors
(Fig 3). General mesenchymal expression of PDGFRs is low in vivo, but increases dramati‐
cally during inflammation and in culture. Several factors induce PDGFR expression, includ‐
ing TGF-β, estrogen (probably linked to hypertrophic smooth muscle responses in the
pregnant uterus), interleukin-1α (IL-1α), basic fibroblast growth factor-2 (FGF-2), tumor ne‐
crosis factor-β, and lipopolysaccharide [55].
Figure 3. adapted from J Andrae 2008): PDGF–PDGFR interactions. Each chain of the PDGF dimer interacts with one
receptor subunit. The active receptor configuration is therefore determined by the ligand dimer configuration. The
top panel shows the interactions that have been demonstrated in cell culture. Hatched arrows indicate weak interac‐
tions or conflicting results.
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The  detailed  expression  patterns  of  the  individual  PDGF  ligands  and  receptors  are
complex.  There  are  some  general  patterns,  however:  PDGF-B  is  mainly  expressed  in
vascular  endothelial  cells,  megakaryocytes,  and  neurons.  PDGF-A  and  PDGF-C  are  ex‐
pressed  in  epithelial  cells,  muscle,  and  neuronal  progenitors.  PDGF-D  expression  is
less  well  characterized,  but  it  has  been observed in  fibroblasts  and SMCs at  certain  lo‐
cations  (possibly  suggesting  autocrine  functions  via  PDGFR-β).  PDGFR-α  is  expressed
in  mesenchymal  cells.  Particularly  strong  expression  of  PDGFR-α  has  been  noticed  in
subtypes  of  mesenchymal  progenitors  in  lung,  skin,  and  intestine  and  in  oligodendro‐
cyte  progenitors  (OPs).  PDGFR-β  is  expressed  in  mesenchyme,  particularly  in  vascular
SMCs (vSMCs) and pericytes.
PDGF biosynthesis and processing are controlled at multiple levels and differ for the differ‐
ent PDGFs. PDGF-A and PDGF-B become disulphide-linked into dimers already as propep‐
tides. PDGF-C and PDGF-D have been less studied on this regard. PDGF-A and PDGF-B
contain N-terminal pro-domains that are removed intracellularly by furin or related propro‐
tein convertases. Likely, PDGF-B also requires N-terminal propeptide removal to become ac‐
tive. In contrast, PDGF-C and PDGF-D are not processed intracellularly but are instead
secreted as latent (conditionally inactive) ligands. Activation in the extracellular space re‐
quires dissociation of the growth factor domain.
Dimerization is the key event in PDGF receptor activation as it allows for receptor auto‐
phosphorylation  on  tyrosine  residues  in  the  intracellular  domain.  Autophosphorylation
activates the receptor kinase and provides docking sites for downstream signaling mole‐
cules and further signal propagation involves protein–protein interactions through specif‐
ic  domains;  e.g.,  Src  homology  2  (SH2)  and  phosphotyrosine  binding  (PTB)  domains
recognizing  phosphorylated  tyrosines,  SH3  domains  recognizing  proline-rich  regions,
pleckstrin  homology (PH)  domains  recognizing membrane phospholipids,  and PDZ do‐
mains  recognizing  C  terminal  specific  sequences.  Most  of  the  PDGFR  effectors  bind  to
specific sites on the phosphorylated receptors through their SH2 domains. Both PDGFR-
α  and PDGFR-β  engage  several  well-characterized  signaling  pathways,  e.g.  Ras-MAPK,
PI3K and PLC-γ, which are known to be involved in multiple cellular and developmen‐
tal responses [56].
The PDGFR is expressed on capillary endothelial cells and PDGF has been shown to have an
angiogenic effect. The effect is, however, weaker than that of fibroblast growth factors or
VEGF, and PDGF does not appear to be of importance for the initial formation of blood ves‐
sels. PDGF B-chain produced by capillaries may have an important role to recruit pericytes
that is likely to be required to promote the structural integrity of the vessels. PDGF has also
been implicated in the regulation of the tonus of blood vessels [57].
PDGF functions have been implicated in a broad range of diseases. For a few of them, i.e.,
some cancers, there is a strong evidence for a causative role of PDGF signaling in this hu‐
man disease process. In these cases, genetic aberrations cause uncontrolled PDGF signaling
in the tumor cells.
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4.3. VEG/PF
Vascular  endothelial  growth/permeability  factor  (VEG/PF)  is  a  40  kda disulphide-linked
dimeric  glycoprotein  that  is  active  in  increasing  blood  vessel  permeability,  endothelial
cell growth and angiogenesis. These properties suggest that the expression of VEG/PF by
tumor cells  could contribute to the increased neovascularization and vessel  permeability
that are associated with tumor vasculature. The cDNA sequence of VEG/PF from human
U937 cells was shown to code for a 189-amino acid polypeptide that is similar in struc‐
ture  to  the  B  chain  of  PDGF-B and other  PDGF-B-related proteins.  The  overall  identity
with PDGF-B is  18%. However,  all  eight  of  the cysteines in PDGF-B were conserved in
human VEG/PF,  an  indication  that  the  folding  of  the  two  proteins  is  probably  similar.
Clusters  of  basic  amino  acids  in  the  COOH-terminal  halves  of  human  VEG/PF  and
PDGF-B are also prevalent. Thus, VEG/PF appears to be related to the PDGF/v-sis family
of proteins [58].
5. Angiogenesis and radiological assessment techniques
Neoangiogenesis,  the  formation  of  new  blood  vessels  from  a  pre-existing  vascular  net‐
work,  is  essential  for tumor growth,  tumor proliferation and metastasis.  The angiogene‐
sis  process is  regulated by different proangiogenic and antiangiogenic factors,  being the
primary  stimulus  of  new  vessel  formation  the  hypoxia  induced  by  expansion  of  the
growing tumor mass [59].
Tumor  angiogenesis  is  an  attractive  target  for  anticancer  therapy,  and a  wide  range  of
novel  therapies  directed  against  tumor  vascularity  has  been  developed.  Because  many
antiangiogenic  agents  are  not  cytotoxic  but  instead produce  disease  stabilization,  meas‐
urement  of  tumor  size  alone  may be  not  informative  regarding  therapeutic  effects.  For
that  reason,  there  has  been  great  interest  in  the  use  of  physiologic,  rather  than  solely
anatomic, imaging techniques [60]. Tumor vascularity has different features that are char‐
acteristic  of  malignancy,  such  as  spatial  heterogeneity,  chaotic  structure,  fragility  and
high permeability  to  macromolecules.  These  structural  abnormalities  of  new tumor ves‐
sels lead to pathophysiologic changes within the neoplastic tissue,  including an increase
in  capillary  permeability,  volume of  extravascular-extracellular  space,  and tumor  perfu‐
sion,  that permit distinction of malignant from benign vascularity with functional imag‐
ing techniques.
Several commonly available imaging modalities, including magnetic resonance (MR), com‐
puted tomography (CT), ultrasound and positron emission tomography (PET), have been
used to indirectly assess the angiogenic status of human tumors [61]. But perfusion imaging
with MR, and specially CT, are the most useful in clinical practice. They have the advantage
of good spatial resolution, minimal invasiveness and rapid acquisition of data. Both techni‐
ques sequentially demonstrate passage of a bolus of contrast medium through a region of
interest and allow quantification of the profile of tissue enhancement.
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6. Perfusion CT
The fundamental principle of perfusion CT is based on the temporal changes in tissue at‐
tenuation after intravenous administration of iodinated contrast material (CM). This en‐
hancement depends on the tissue iodine concentration, existing a direct linear relationship
between contrast concentration and CT enhancement [62].
Recent progress in multidetector CT technology has enabled the rapid scanning of large ana‐
tomic volumes with high resolution. In perfusion CT, repeated series of images of the vol‐
ume analyzed are performed in quick succession before, during and after intravenous
administration of CM. The ensuing tissue enhancement can be divided into two phases
based on CM distribution: a initial phase where the enhancement is attributable to the distri‐
bution of contrast within the intravascular space (“first pass”, lasting 40-60 secs. from the
contrast arrival), and a second phase as contrast diffuses from the intravascular to the ex‐
travascular compartment across the capillary basement membrane (2-5 minutes duration).
To objectively quantify the “real” perfusion parameters of tissues from the density differ‐
ence produced by the contribution of contrast material, a mathematic model is applied to
the dynamic CT data. The quantitative parameters generated include blood volume (BV),
blood flow (BF), mean transit time and capillary permeability surface.
Perfusion CT is a biomarker for angiogenesis that have been validated with other surrogate
markers, such as VEGF levels, tumor perfusion and microvascular density (Fig 4) [63]. There
has been a gradual increase of its use in oncology, ranging the wide spectrum of clinical ap‐
plications of this technique, from lesion characterization, (differentiation between benign
and malignant lesions), to prognostic information based on tumor vascularity and monitor‐
ing therapeutic effects of chemoradiation and antiangiogenic drugs. In a recent study using
a 320-detector row CT, Ohno et al. concluded that perfusion CT has the potential to be more
specific and accurate than PET/CT for differentiating malignant from benign pulmonary
nodules [64]. Another study have also shown that in patients with NSCLC treated with sora‐
fenib and erlotinib, early changes in tumor blood flow were predictive of objective response
and tended to indicate a longer progression-free survival [65].
Figure 4. Parametric maps of perfusion CT studies representing blood flow in two different patients with NSCLC. (A) Tumor
with very low perfusion depicted in blue and (B) a highly vascularized neoplasm showing yellow and red zones (scale at left).
Angiogenesis and Lung Cancer
http://dx.doi.org/10.5772/54309
13
Radiation exposure, the requirement of long breath holding during chest imaging acquisi‐
tion and lack of standardized protocols, remain potential drawbacks of this technique. How‐
ever, implementation of low-dose scanning strategies may allow a more widespread use in
the future.
7. Dynamic MR
Quantification of tumor vascularity by dynamic MR (DCE MR) is technically more challeng‐
ing than perfusion CT because there is a lack of a direct relationship between MR signal in‐
tensity and contrast agent concentration. This is due to the fact that tissue signal intensity on
MR is related to the effect of CM on water in the microenvironment, which changes tissue
relaxivity in complex and unpredictable ways [66].
While perfusion CT yield information is based predominantly on the first pass of CM (BV,
BF), the MR imaging technique may sample a volume of interest over a longer time and
yields parameters that reflect microvessel perfusion, permeability and extracellular leakage
of space. In addition, by applying pharmacokinetic models to the MR imaging acquisitions,
it is possible to calculate quantitative parameters, such as the transfer constant (Ktrans) that
describes the transendothelial transport of the CM.
A central flaw of dynamic MR is that acquisition and pharmacokinetic models vary widely.
Thus, comparing studies from different institutions is difficult. This technique, on the other
hand, is of limited value in organs with physiological movement such as the lungs.
Few studies have applied dynamic MR in the assessment of lung cancer. Ohno et al [67]
evaluated the role of DCE MR as a prognostic indicator in NSCLC patients treated with che‐
motherapy using cisplatin and vincristine. In their study, the mean survival period of pa‐
tients with lower slope of enhancement was significantly longer than that seen in the group
with higher slope of enhancement. This study provides promising data for the application of
dynamic MR in response assessment to chemotherapy and targeted therapy.
8. Current state of antiangiogenic therapy for NSCLC: VEGF as target
treatment
In this section, we analyze the activity of a monoclonal antibody (bevacizumab) and other
new antiangiogenic therapies.
8.1. Bevacizumab
Bevacizumab is a monoclonal antibody directed against VEGF and was the first antiangio‐
genic drug approved for the treatment of advanced NSCLC. Currently it’s the only ap‐
proved in this setting in Europe and the USA.
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After  proving the improvement in  the response rate  (RR) and progression free survival
(PFS) of bevacizumab together with chemotherapy in first line in a randomized phase II
study in which 99 patients with advanced or metastatic NSCLC were included [68],  the
ECOG group undertook a phase III trial (ECOG 4599) in first line, in which patients with
brain metastasis,  hemoptysis,  and squamous histology were excluded, due to the risk of
hemoptysis observed in the previous study with this histology [69]. The studied random‐
ized  878  patients  with  recurrent  or  advanced  NSCLC  to  receive  carboplatin/paclitaxel
with or  without  bevacizumab on a  dose of  15 mg/kg every 21 days and crossover  was
not  allowed.  The  main  objective,  overall  survival  (OS),  was  improved  in  the  trial  arm:
12.3 months vs 10.3 months,  with a hazard ratio (HR):  0.79 (95% CI:  0.67-0.92;  p=0.003).
In addition, the RR was also improved (35 vs 15% (p<0.001)) and the PFS went from 4.5
to  6.2  months  (HR:  0.66;  95% CI:  0.57-0-77,  p<0.001).  However,  adding  bevacizumab to
the chemotherapy also increased toxicity; there were 15 toxic deaths (2 in the arm of che‐
motherapy alone) due to pulmonary hemorrhage, digestive bleeding, febrile neutropenia,
ictus and lung embolism. A subgroup analysis found that patients over 70 had a higher
incidence of grade 3-5 toxicities (87 vs 61%).
The AVAiL study [70] randomized 1043 patients to receive cisplatin and gemcitabine with
or without bevacizumab in a dose of 7.5 or 15 mg/kg each 21 days. In this study the main
goal was PFS, which was higher in patients which received the drug than those who took
placebo, both in small dose arm (6.7 months vs 6.1 months; HR: 0.75, p=0.003) as well as in
higher one (6.5 months vs 6.1 months, HR: 0.82, p=0.03). Nevertheless, OS didn’t improve,
which could be explained by the high percentage of patients who received treatment after‐
wards (more than 60%). Regarding toxicity, 7 patients died due to lung hemorrhage in the
trial arm (2 in the control trial), although it was observed that in patients who were under
anticoagulant treatment there was no lung hemorrhage.
The SAiL safety study, which included more than 2000 patients, showed the effectiveness of
combining other doublets of chemotherapy; in terms of safety it displayed a grade 3 or high‐
er lung hemorrhage incidence only in 1% of the patients [71].
An efficiency meta-analysis published in 2011 confirms effectiveness in terms of PFS, pre‐
senting uncertainty in terms of improvement of OS [72].
A meta-analysis published recently with 2210 patients evaluated the bevacizumab toxicity
profile with high dose of bevacizumab (15 mg/kg), and stated that bevacizumab is related to
a higher risk of toxicity deaths (HR: 2.04; 95% CI: 1.18-3.52), but it was not the case in lower
doses of 7.5 mg/kg (HR: 1.20; 95% CI: 0.60-2.41). In addition, bevacizumab was associated to
a greater incidence of grade 3-4 toxicities, especially in the group of high doses [73].
More studies have been conducted in sub-populations, for example, the PASSPORT study in
109 patients with brain metastasis, subgroup that had not been included in previous studies,
and which proved that bevacizumab can be administrated in patients with controlled brain
metastasis [74]. Another review on the incidence of bleeding in patients with brain metasta‐
sis treated with antiangiogenic drugs proved to be safe when it is administered to treated
patients as well as patients with metastasis that appears during treatment [75].
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The combination of bevacizumab with some of the new agents has been studied as well.
In  the  ATLAS study,  after  having received four  cycles  of  cisplatin-based chemotherapy
and bevacizumab, patients were randomized to receive treatment with bevacizumab (15
mg/kg)  and  erlotinib  (150  mg  daily)  or  only  bevacizumab.  The  main  objective  of  this
study was reached (PFS),  with 4.8 months vs 3.7 months (HR: 0.72,  p=0.0012);  neverthe‐
less  no  improvement  was  made  in  OS,  a  secondary  goal  of  the  study  (14.4  months  vs
13.3 months; p=0.56) [76].
The phase III BeTa trial compared the activity of the combination of bevacizumab and erloti‐
nib vs erlotinib in second line in 636 patients. An improvement in PFS was found (3.4 vs 1.7
months; HR: 0.62, p<0.0001), but again, no significant differences were found in OS (9.3 vs
9.2 months; p=0.75)
Hypertension has been found to be a marker of clinical benefit from bevacizumab in var‐
ious malignancies [77],  although no single biomarker have proven to be ready for clini‐
cal  use.  Cytokines  and  angiogenic  factors  profiling  may  help  identify  drug-specific
markers of activity.
8.2. Aflibercept
Aflibercept (VEGF-Trap) is a recombining fusion protein, which is added to VEGFR-1,
VEGFR-2 and to the placental growth factor (PlGF).
In a phase II trial in patients with lung adenocarcinoma treated after several treatment lines,
aflibercept in a dose of 4 mg/kg was administered intravenously every 14 days, reaching a
RR of 2%, with a PFS of 2.7 months and an OS of 6.2 months [78]. A phase III trial in second
line after failure to cisplatin-based chemotherapy compared aflibercept vs docetaxel (VITAL
trial). This trial showed an improved RR (23.3& vs 8.9%) and PFS (HR: 0.82), but the primary
endpoint, OS, was not reached (HR: 1.01).
9. Vascular disrupting agents
Vadimezan, fosbretabulin and plinabulin are vascular disrupting agents (VDA); fosbretabu‐
lin selectively disrupts VE-cadherin and plinabulin acts on cytoskeleton. A phase II trial of
carboplatin, paclitaxel, bevacizumab and fosbretabulin was well tolerated and with a trend
to improve OS and PFS [79], also a phase II trial with docetaxel with or without plinabulin
showed a higher response rate with the combination (55% vs 5%) [80]; however, a random‐
ized phase III study with vadimezan in first line failed to show an improvement in OS [81].
10. Multi-targeted tyrosine kinase inhibitors
Several anti-angiogenic small-molecule tyrosine kinase inhibitors (TKIs) are in current clini‐
cal development. An advantage of TKIs includes the fact that they inhibit multiple receptors
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simultaneously, with anti-angiogenic and anti-proliferative activity against NSCLC, thereby
potentially providing a higher likelihood of single-agent activity. Another benefit is that
these agents are often available orally, offering patients greater convenience. However, tox‐
icity remains a concern given the multi-targeted kinase inhibition and the additive adverse
effects that may be of particular concern when the agents are combined with chemotherapy.
11. Sorafenib
Sorafenib is an oral multi-kinase inhibitor of VEGFR-2 and -3, PDGFR-β, RAF-kinase, c-Kit,
RET, and Ftl-3.
In the phase II ECOG 2501 trial, 342 patients with NSCLC who has failed at least two prior
chemotherapy regimens received sorafenib for two cycles. Those patients who were noted to
have stable disease after two cycles (n = 97) were randomized to receive sorafenib or place‐
bo. Sorafenib prolonged PFS compared with placebo (3.6 versus 1.9 months) [82]. In another
phase II trial, of 52 patients with relapsed or refractory advanced NSCLC, 59% achieved SD,
and in these patients, median PFS was 5.5 months [83].
The results of two phase III trials in the first-line treatment of NSCLC, ESCAPE (sorafenib
plus paclitaxel/carboplatin) and NEXUS (sorafenib plus gemcitabine/cisplatin), were unsat‐
isfactory. Because of the safety findings from the ESCAPE trial, patients with squamous cell
histology were withdrawn from the NEXUS trial in February 2008 and excluded from analy‐
sis. Median OS, the primary endpoint of both trials, was similar in the sorafenib and placebo
groups [84,85].
The Biomarker-Integrated Approaches of Targeted Therapy for Lung Cancer Elimination
(BATTLE) study randomized pretreated lung cancer patients to erlotinib, vandetanib, erloti‐
nib plus bexarotene or sorafenib based upon biomarker results obtained from individual pa‐
tients. K-ras-mutant patients treated with sorafenib had a non-statistically significant trend
toward improved disease control rate (DCR) (61 versus 32%, p = 0.11), suggesting a prefer‐
ential benefit of sorafenib in k-ras-mutant patients [86].
Phase III MISSION trial of sorafenib in patients with advanced relapsed or refractory non-
squamous NSCLC whose disease progressed after two or three previous treatments, did not
meet its primary endpoint of improving OS. An improvement in the secondary endpoint of
PFS was observed [87].
These findings have led to suspend the development of sorafenib in NSCLC.
12. Vandetanib
Vandetanib is an oral TKI that inhibits VEGFR-2 and -3, RET and EGFR.
Vandetanib in combination with carboplatin/paclitaxel resulted in prolonged PFS (56 weeks;
HR= 0.76, p= 0.098) compared with carboplatin/paclitaxel alone (52 weeks) in previously un‐
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treated patients with advanced NSCLC. The secondary endpoint of OS was not significantly
different between the two arms [88]. Another phase II trial showed that vandetanib in com‐
bination with docetaxel was superior to docetaxel alone in pretreated NSCLC patients with
regard to PFS (18.7 weeks versus 12 weeks; HR = 0.64, p = 0.037) [89].
The phase III ZODIAC trial randomized patients with advanced NSCLC to receive either
docetaxel/vandetanib or docetaxel/placebo as second-line treatment. Although vandetanib
improved ORR (17 versus 10%, p= 0.0001) and PFS (HR: 0.79, p< 0.0001), OS was not signifi‐
cantly improved (HR: 0.91, p= 0.196) [90]. In the ZEAL trial, vandetanib was investigated in
combination with pemetrexed also in the second-line setting. Despite an improvement in
ORR (19 versus 8%, p < 0.001), this study did not meet its primary endpoint of PFS (HR:
0.86, p = 0.108) [91]. In another phase III trial (ZEPHYR), patients who had progressed after
chemotherapy and erlotinib were randomized to vandetanib versus placebo. PFS was im‐
proved (HR: 0.63, p < 0.0001), but not OS (HR: 0.95, p = 0.527) [92]. The above phase III trials
did not carry out stratified analysis on the EGFR gene status and therefore were not able to
further identify the potential populations that may benefit from vandetanib.
These results led to withdrawal of the application for approval of vandetanib in NSCLC.
13. Sunitinib
Sunitinib is an oral TKI of VEGFR-1, -2, -3, PDGFR-α/β, c-kit, Flt-3 and RET.
It has been studied in advanced NSCLC in two phase II trials. In the first one, 63 pretreated
patients received sunitinib as single agent, achieving an ORR of 11.1% (95%CI: 4.6–21.6), me‐
dian PFS of 12 weeks (95%CI: 10.0-16.1) and median OS of 23.4 weeks (95%CI: 17.0-28.3)
[93]. In the other phase II trial, 47 pretreated patients received sunitinib on a continuous-
dosing schedule (37.5 mg/day). The ORR was only 2.1%, but median PFS and OS were 11.9
weeks (95%CI: 8.6-14.1) and 37.1 weeks (95%CI: 31.1-69.7), respectively [94].
There are ongoing studies investigating sunitinib in patients with NSCLC, including the
phase II CALGB 30704 trial evaluating sunitinib as second-line therapy and the phase III
CALGB 30607 study of sunitinib as maintenance therapy.
14. Other multi-targeted TKIs
Axitinib, with VEGFR, PDGFR-β and c-Kit as its main targets, is currently the most potent
TKI in inhibiting VEGFR signal pathways. In a phase II study in advanced NSCLC, in which
28% of patients had received no prior chemotherapy, ORR was 9.4%, with PFS and OS of 4.9
and 14.8 months, respectively [95]. Currently, three ongoing phase II studies are exploring
the effectiveness and safety of axitinib-based combination therapies in non-squamous
(AGILE1030: with paclitaxel/carboplatin; AGILE1039: with pemetrexed/cisplatin) and squa‐
mous NSCLC (AGILE1038: with cisplatin/gemcitabine).
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Motesanib mainly inhibits targets including VEGFR, PDGFR, c-Kit and RET. In a phase II
study of motesanib or bevacizumab in combination with carboplatin/paclitaxel as frontline
treatment for advanced non-squamous NSCLC, the efficacy was similar, with a median PFS
of 7.7 months (versus 8.3 months with bevacizumab) and a median OS of 14.0 months in
both arms [96]. However, the phase III study of motesanib plus carboplatin/paclitaxel in pa‐
tients with non-squamous advanced NSCLC (MONET1) did not meet its primary endpoint
of improved OS (HR: 0.89, p = 0.137) [97].
BIBF 1120 inhibits VEGFR-1, -2 and -3, in addition to PDGFR-α/β and FGFR-1-3. In a phase
II trial of 73 patients with relapsed or advanced NSCLC, the median PFS and OS were 11.6
and 37.7 weeks, respectively, with a disease control rate (DCR) of 46% [98]. BIBF 1120 is be‐
ing studied, in the second-line NSCLC setting, in two phase III trials, in combination with
docetaxel (LUME-Lung 1) and with pemetrexed (LUME-Lung 2).
A phase Ib/II  study of  cabozantinib,  a  TKI with potent  activity  against  MET,  VEGFR-2,
RET,  c-Kit  and Ftl-3,  with  or  without  erlotinib  in  pretreated  advanced NSCLC patients
showed  that  the  combination  was  well  tolerated  with  evidence  of  clinical  activity  in  a
largely  erlotinib  pretreated  cohort,  including  patients  with  EGFR  T790M  mutation  and
MET amplification [99].
Another multikinase inhibitors like pazopanib are in an earlier stage of development.
Although multitargeted TKIs have made certain advances in treating NSCLC, the outcomes
remain unsatisfactory if they were applied non-selectively among NSCLC patients. Among
the non-selective populations, TKI monotherapies showed no significant differences when
compared with mono-targeted agent therapies (erlotinib, gefitinib) in treating NSCLC in
terms of ORR, PFS and OS. Therefore, it is extremely important to identify populations that
are suitable for TKIs. The future of multi-targeted drugs is highly depended on the capabili‐
ty of delivering these molecule-targeted therapies to patients most likely to benefit.
15. Conclusions
In recent years, we have acquired a lot of information regarding the role of angiogenesis
and its pathophysiological relationship with some types of neoplasias, engaging in proc‐
esses  such as  tumour growth and dissemination capacity  as  loco-regional  as  distant.  In
lung cancer,  we know that neoangiogenesis is  the result  of the action of several growth
factors  (mainly VEGF,  TGF-alpha,  EGF,  VEG/PF and PDGF) whose output  is  controlled
by transcription factors hypoxia-induced such as HIF-1, whose expression has been asso‐
ciated as an independent factor of poor prognosis. Acquired knowledge has allowed de‐
signing  therapeutic  strategies  aimed  at  blocking  the  action  of  various  pro-angiogenic
factors and thereby altering the disease natural course. Some drugs acting against VEGF,
as  bevacizumab,  have  demonstrated  clinical  efficacy  improving  OS  and  PFS  although
with  treatment-related  toxicities  expected  with  blocking  this  pathway,  as  showed some
trials,  particularly in patients subsets with a known clinical  profile that when is present
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makes it more susceptible to those complications. Another line of research has been that
of small-molecule tyrosine kinase inhibitors (sorafenib, vandetanib, sunitinib, axitinib, pa‐
zopanib and motesanib), showing some benefits in PFS but without a positive impact in
OS when were applied non-selectively among NSCLC patients, so in the future probably
we will need identify populations with a right profile that allows us to predict who have
more chance to benefit from this therapy. Structural abnormalities in tumor neovasculari‐
zation lead to pathophysiological changes within the neoplastic tissue. The study of these
functional changes have allowed to develop imaging techniques that, not only differenti‐
ate  a  benign  lesion  from other  malignant,  but  also  provide  prognostic  information  and
monitor  the  therapeutic  effects  of  drugs  used.  Thus,  techniques  such  as  perfusion  CT
and dynamic MR allow anatomical and functional assessment of neoplasia, based on the
characteristics and changes of intratumoral capillary network.
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